Morgan Stanley maintains Legend Biotech at Overweight, lowers price target to $43 from $49
Morgan Stanley kept its Overweight rating on Legend Biotech but cut its price target to $43 from $49, a 12.2% reduction. The new target suggests a 110.7% upside from the Nov 10 closing price of $20.41, according to the firm.
How this was made

The 30-second read
Why it matters
Analyst target reductions can trigger short-term sell pressure, especially for low‑float stocks.
Market read
The downgrade provides a fresh data point for traders monitoring micro‑cap biotech equities.
What to watch
Potential pipeline milestones not reflected in the downgrade.
Background
Morgan Stanley's rating maintenance at Overweight with a lower price target reflects a shift in valuation expectations.
Market effects
Biotech sector may see modest downside as analyst cuts spread.
US biotech investors could adjust exposure.
Limited, primarily US micro‑cap focus.
Counterpoint
The target cut may be overly cautious if upcoming trial data is positive.
Key entities
- companyLegend Biotech
US‑listed biotech (ticker LGND) subject of the analyst downgrade.
- analyst_firmMorgan Stanley
Equity research firm issuing the price target change.


